Key Drivers
- Strong liquidity
- Weak margins
- High valuation
AIAI Summary
PRVA has transformed from a cash‑burn roll‑up into a debt‑free, cash‑generative platform, making the investment thesis an execution bet on converting attributed‑life growth and disciplined M&A into sustained EBITDA and GAAP margin expansion rather than on financing survival. Monitor three actionable signals closely—quarterly GAAP margin improvement (not just adjusted EBITDA), sustained mid‑teens EBITDA growth guidance delivery, and early, measurable synergies from the Evolent ACO integration—because failure on any will likely trigger sharp multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Weak margins
- •High valuation
PRVA has strong liquidity and FCF with negligible debt but weak profitability and very high valuation that raise sustainability concerns.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Oversold momentum
- •Defined support zone
PRVA is trading below its last-month SMA (≈$22.65) with an oversold RSI (~23), suggesting short-term downside pressure but a higher chance of a mean-reversion bounce off defined support around $21.20–$21.70.
RSI near 23 indicates unusually oversold conditions that may precede a bounce
Sentiment & News
Key News Insights:
- •Robust profitability
- •Debt-free balance
- •20% EBITDA guide
Privia reported robust FY25 results with net income +59%, adj. EBITDA +38.8%, debt-free $479.7M cash, Q4 EPS beat, 2026 guidance targeting ~20% adj. EBITDA growth, rising analyst optimism and a strong 84% colorectal screening rate.
This strengthens the investment case—operational momentum and clean balance sheet should support share-price upside and analyst targets
Similar Companies in Healthcare
Other companies in the same sector with AI ratings